Cadila Healthcare’s vaccine bet keeps sentiment upbeat1 min read 06 Jan 2021, 05:14 AM IST
Timely approvals of complex opportunities will be key to offsetting the erosion in the base business, say analysts
The news flow around covid-19 vaccines has kept Cadila Healthcare Ltd’s shares under the investors’ radar. The company has completed phase 2 clinical trials for ZyCoV-D, the indigenously developed vaccine, and has also received approvals to conduct phase 3 trials.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started
Select your Category